At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Anakinra, Axicabtagene Ciloleucel, and 2 other interventions for Hematopoietic and Lymphoid Cell Neoplasm and 8 related conditions. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene ciloleucel in patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Anakinra is a drug typically used to treat rheumatoid arthritis but may also help in reducing CAR-T cell therapy toxicity. Giving anakinra in combination with axicabtagene ciloleucel may help control relapsed or refractory large B-cell lymphoma.
Study Details
Timeline
Interventions
Given SC
Given IV
Given IV
Given IV